Comorbid conditions have not been studied systematically for impact upon patient outcome in the setting of hematopoietic stem cell transplantation (HSCT). Patients formerly excluded from myeloablative transplant due to comorbid illnesses now receive reduced-intensity conditioning regimens; hence, the incidence of comorbid conditions in HSCT recipients is expected to increase. Comorbid grading systems developed without regard for oncology patients have been applied in retrospective fashion to HSCT patients. Two commonly used scales (Charlson Comorbidity Index and the Adult Comorbidity Inventory-27) fail to include critical information: tumor and histologic type/stage, extent of prior treatment, donor stem cell source and cell type and preparative regimen. Further, data are reported in retrospective rather than prospective fashion. Despite limitations, however, such grading systems exhibit ease and utility for evaluation and may have predictive value for patient outcome. Modifying such approaches to include additional factors and appropriate weighting of components may enable an improved comparison of techniques and study results. These scoring systems may elucidate predictors of outcome and disease natural history and enhance statistical efficiency methods of HSCT. Refined scoring could be used effectively to assign patients to differing transplant conditioning regimens, that is, myeloablative vs reduced intensity. Prospective validation of such grading systems is encouraged. Bone Marrow Transplantation (2005) 36, 475-479.
conditioning; allogeneic; comorbidity index Comorbidities are defined as any concurrent health condition or process that coexist with an index disease or procedure that is being studied. Comorbidities can affect the moment of detection, prognosis, therapy and patient outcome in a variety of diseases. 1 With the advent of nonablative conditioning regimens, and the documented survival benefit of autografting in a variety of hematologic malignancies that affect older individuals, the median as well as the upper age limit for the hematopoietic stem cell transplant recipient has increased. 2 With the increasing age of the transplant recipient, the incidence of comorbid conditions in this population is expected to increase. Comorbid conditions, with the possible exception of advanced age, have not been systematically studied for their impact upon patient outcome in the setting of hematopoietic progenitor cell transplantation. The relevance of these factors on transplant outcomes needs to be studied, as well as the impact of hematopoietic transplantation on the natural history of these comorbid conditions. 3, 4 Single organ comorbidities prior to transplant
In the context of progenitor cell transplantation, single organ comorbidities prior to transplant have been studied extensively as predictors for organ toxicity and transplant outcomes. One of the most relevant papers reviewing this issue was reported recently by Bolwell 5 in this journal. Many of the most important single organ comorbidities as predictors of transplant outcomes and the relevant references are briefly summarized in Table 1. 6-17 These publications, in general, demonstrated that pre-transplant cardio-pulmonary testing did not predict for adverse outcome. [6] [7] [8] [9] [10] Using retrospective data analyses, Goldberg et al 11 reported that reduced FEV1 (o78% predicted) correlated with respiratory mortality and Jain et al 9 noted that a severe decrease in diffusion pre-transplant predicted respiratory failure. Other investigators, however, have failed to demonstrate that pre-transplant lung function studies are capable of predicting patient outcomes. [12] [13] [14] Of all single organ comorbidities studied, the presence of abnormal liver function tests (primarily elevated serum transaminases) has been the most predictive of tissue specific toxicity post transplant. Thus, patients with elevated transaminases have a three-to six-fold increased risk of developing moderate to severe hepatic veno-occlusive disease after transplant. [15] [16] [17] [18] Similarly, pre-transplant elevations of serum creatinine have been associated with higher rates of post transplant dialysis use and mortality. 19, 20 None of the single organ comorbidities studied to date is sufficiently predictive of transplant outcome to allow for effective decision-making. Furthermore, many patients currently undergoing progenitor cell transplantation for malignancies have more than one comorbid condition. These observations obligate the transplant community to examine the current methods that assess and score multiple comorbid conditions as potential predictors of transplant outcomes. In this review we summarize potential methods of comorbidity scoring, preliminary data and potential pitfalls for the application of these methods in the setting of progenitor cell transplantation.
Surrogate comorbidity markers
Although not specifically considered one of the comorbidity indices, both age and performance status (PS) are used as predictive factors that encompass more than one organ site. Previous reviews of age on transplant outcome yielded conflicting results, some studies showing higher risk while others demonstrated no effect at all. The impact of age on transplant outcome has been reviewed by Popplewell and Forman 2 and Bolwell. 5 Although older patients tend to have higher nonrelapse mortality rates and lower survivals, age by itself should not be used as criteria to include or exclude a patient from transplant. PS, as defined by either the Karnofsky or Zubrod scales, represents a simplified tool of functional assessment and does not account for the presence or absence of specific comorbidities. 21, 22 PS has been extensively explored as a prognostic factor for outcomes after progenitor cell transplantation, with most large series of both allogeneic and autologous transplant demonstrating that nonrelapse mortality and survival are related to PS scores. 23, 24 Very few patients with PS42 or Karnofskyo70, however, actually are transplanted, thus limiting the utility of PS as a discriminator.
Patient weight also has been studied as a prognostic factor for transplant-related mortality. Deeg 28 separately reported two comorbid rating scales to assess geriatric and physical therapy candidates, respectively. de Groot et al 29 recently reported a critical reappraisal of methods to measure comorbidity. In the context of other disorders, comorbidity indices have been extensively studied and have been the subjects of extensive reviews.
29-31
The most common comorbidity indices and their characteristics have been summarized in Table 2. 32-36 Of the 13 methods assessed by de Groot et al, 29 they noted the Charlson Comorbidity Index (CCI) 32 that evaluates the presence or absence of 19 conditions and scores and weighs their severity to be the most extensively studied for predicting mortality. These indices, however, have never been compared to each other in a prospective manner and have all been shown to be valid and reliable tools for measuring comorbidity in clinical research.
Comorbidity indices have been developed and applied to a wide variety of medical conditions running the gamut from motor impairment and disability in Parkinson's disease to end-stage renal disease and dialysis. [36] [37] [38] [39] [40] [41] [42] Within the field of oncology, such indices have been used to assess head and neck cancer patients, 36 prostate cancer, 40 colon cancer 41 and breast cancer, 42 to name a few. These tools appear to be useful for intervention studies and as a prognostic aid for clinicians. These instruments also can be used to correct for confounding variables, identify effect modification, and enhance statistical efficiency when comparing or performing clinical trials.
Comorbidity indices in hematopoietic stem cell transplantation (HSCT)
The use of standard comorbidity indices as predictors of transplant outcomes or as instruments to allocate patients to specific transplant therapies has not been studied indepth. Shahjahan et al 43 at MD Anderson retrospectively analyzed a cohort of acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) patients in order to determine the impact of comorbidities on the outcome of allogeneic HSCT. They used an adaptation of the CCI to obtain a weighted composite score for all pretransplant comorbid conditions. In their analysis of 78 AML first remission patients, the authors reported that higher CCI scores (CCI42 vs CCI 0-2) correlated with higher nonrelapse mortality at 100 days (14 vs 3%, P ¼ 0.08) and at 1 year (26 vs 4%, P ¼ 0.03) after transplant. Furthermore, overall survival at 2-years after transplant was lower in those subjects with higher CCI scores, 38 vs 76% (P ¼ 0.003). These correlations held true for younger patients (o40 years of age) as well. 43 In this study, 22% of patients had no comorbid conditions other than their malignant disease and an additional 14% had only one other comorbidity, usually age greater than 40 years, secondary leukemia or diabetes mellitus.
In a study from the Fred Hutchinson Cancer Research Center, Sorror et al 44 reported their results of a retrospective analysis of hematologic malignancy patients, who received matched unrelated HSCT after a myeloablative (N ¼ 74) or nonmyeloablative (N ¼ 60) conditioning regimen. Pre-transplant comorbidities also were scored per CCI in that study. The authors concluded from their analysis that higher pre-transplant CCI score was an independent risk factor for higher transplant-related toxicity and nonrelapse mortality. 44 This center also recently reported a similar retrospective analysis conducted in HLA matched-related donors who received a myeloablative (N ¼ 73) vs a reduced-intensity conditioning regimen (N ¼ 73). 45 Despite nonmyeloablative patients having worse characteristics such as higher CCI scores, older age and other adverse factors, the nonrelapse mortality rates at day 100 and at 1 year after transplant were significantly lower compared to myeloablative transplants, 3 vs 23% (P ¼ 0.0001) and 16 vs 30% (P ¼ 0.04), respectively. They concluded that the CCI score appeared to be a valuable tool for predicting nonrelapse mortality and was potentially useful in deciding the type of conditioning a patient should receive. ) years and 55% of the patients received cells from an HLA-identical sibling donor. In total, 53% of patients scored at least one point for a comorbid condition as assessed by KF, as opposed to 25% by CCI (Po0.001) and 28% scored at least 2 points by KF vs 8% by CCI (Po0.001). Comorbidity, PS and age greater than 50 years predicted increased nonrelapse mortality. 46 Sorror et al 47 recently reported a refinement of the CCI to account for some transplant-specific factors such as prior infection. Of interest was the fact that in the training set some comorbidities had higher weighted scores than the original CCI had assigned them. This modified CCI segregated patients into three risk categories for transplant-related mortality. Patients with scores of 0, 1-2, and X3 had transplant-related mortality rates of 13, 24, and 40%, respectively. When the score was applied to patients receiving either nonablative or ablative conditioning regimens, the transplant-related mortality rate was significantly different only in patients with scores of less than 3 (17 vs 27% (P ¼ 0.002) for scores 1-2, and 39 vs 42% (P ¼ 0.18) for scores X3). These data suggest that comorbidity scoring can be used to assign patients to different conditioning regimens. 47 
Limitations of comorbidity indices
The CCI and the Adult Comorbidity Inventory-27 are the two most widely used grading systems for oncology. These systems were not developed specifically for cancer patients. Thus, critical information such as stage of disease, type and extent of prior therapy, complications of prior therapy as well as history of infectious complications are not included in the assessment and do not receive appropriate weighting. Further, the data reported to date are retrospective rather than prospective in nature, rely upon chart or medical record abstraction and often have not been validated with respect to performance. The utility and ease of use as well as time required for analysis of these indices also has not been defined. Nonetheless, despite the potential limitations of comorbidity indices, we conclude that although grading systems such as the CCI may be useful tools to assign patients to different strategies of progenitor cell transplantation, transplant specific scoring systems should be developed.
Functional assessment of the prospective patient may also provide important prognostic information for patients undergoing progenitor cell transplantation. In the setting of conventional chemotherapy functional assessment has predicted toxicity in older cancer patients. The combination of comorbidity indices with measurements of functional assessments (ie 'get up and go tests' or 'activities of daily living') have been used together and seem to provide an important tool to predict tolerance and outcomes after medical interventions; these combined assessments may have enough predictive power to define who truly is 'not a progenitor cell transplant candidate'. [48] [49] [50] [51] 
